Journal
NATURE REVIEWS CARDIOLOGY
Volume 16, Issue 1, Pages 33-55Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41569-018-0074-0
Keywords
-
Categories
Funding
- Polish National Science Centre [UMO-2014/15/B/NZ1/00490]
- Glenn Foundation for Medical Research
- Sinclair Gift Fund
- US NIH/National Institute on Aging [R01 AG028730, R01 DK100263]
- Ligue Nationale contre le Cancer Comite de Charente-Maritime (equipe labellisee)
- Agence National de la Recherche (ANR) - Projets blancs
- ANR
- ERA-Net for Research on Rare Diseases
- Association pour la recherche sur le cancer (ARC)
- Canceropole Ile-de-France
- Fondation pour la Recherche Medicale (FRM)
- European Commission (ArtForce)
- European Research Council (ERC)
- Fondation Carrefour
- Institut National du Cancer (INCa)
- INSERM (HTE)
- Institut Universitaire de France
- LeDucq Foundation
- LabEx Immuno-Oncology
- Seerave Foundation
- SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE)
- SIRIC Cancer Research and Personalized Medicine (CARPEM)
- Paris Alliance of Cancer Research Institutes (PACRI)
- Italian Ministry of Education, the University and Research
- Telethon [GGP15219/B]
- Italian Association for Cancer Research (AIRC) [IG-18624]
- University of Ferrara (Ferrara, Italy)
- Department of Radiation Oncology at Weill Cornell Medicine (New York, NY, USA)
- Chancelerie des universites de Paris (Legs Poix)
- RHU Torino Lumiere
- NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R21DE027490] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK100263] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE ON AGING [R01AG019719, DP1AG058605, R37AG028730] Funding Source: NIH RePORTER
Ask authors/readers for more resources
A large body of evidence indicates that mitochondrial dysfunction has a major role in the pathogenesis of multiple cardiovascular disorders. Over the past 2 decades, extraordinary efforts have been focused on the development of agents that specifically target mitochondria for the treatment of cardiovascular disease. Despite such an intensive wave of investigation, no drugs specifically conceived to modulate mitochondrial functions are currently available for the clinical management of cardiovascular disease. In this Review, we discuss the therapeutic potential of targeting mitochondria in patients with cardiovascular disease, examine the obstacles that have restrained the development of mitochondria-targeting agents thus far, and identify strategies that might empower the full clinical potential of this approach.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available